4 results
To provide continued bevacizumab therapy as single agent or in combination with an anti-cancer drug to patients with cancer, who were previously enrolled in a F. Hoffmann-La Roche (Roche)/ Genentech sponsored bevacizumab study (i.e. the Parent, P-…
The primary objective of this study is to examine the effectiveness of the use of a load-reducing orthosis for two months on functioning (using a validated osteoarthritis function questionnaire (WOMAC)) in ten patients with osteoarthritis of the…
1. The primary objective of this phase I/II clinical trial is to evaluate the safety and toxicity of ACT plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that does not result in treatment…
The primary objective of this study is to investigate if an orthosis combined with exercise therapy results in less pain and less conversion to surgery than an orthosis alone in patients with CMC-1 OA at three months and one year after treatment…